secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060481
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director
--------------------------------------------------------------------------------

- Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.
- Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.
- CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.
- David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.
- Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/cgem-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer